68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

Isabel Rauscher; Tobias Maurer; Wolfgang P. Fendler; Wieland H. Sommer; Markus Schwaiger; Matthias Eiber

doi:10.1186/s40644-016-0072-6

⁶⁸Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

Isabel Rauscher, Tobias Maurer, Wolfgang P. Fendler, Wieland H. Sommer, Markus Schwaiger, Matthias Eiber

Publikation: Beitrag in Fachzeitschrift › Übersichtsartikel › Begutachtung

161 Zitate (Scopus)

Abstract

Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with ⁶⁸Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with ⁶⁸Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of ⁶⁸Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.

Originalsprache	Englisch
Aufsatznummer	14
Fachzeitschrift	Cancer Imaging
Jahrgang	16
Ausgabenummer	1
DOIs	https://doi.org/10.1186/s40644-016-0072-6
Publikationsstatus	Veröffentlicht - 8 Juni 2016

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1186/s40644-016-0072-6

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{a26d83e33b004b2d9b779623a1c951ab,

title = "68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report",

abstract = "Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.",

keywords = "Positron emission tomography, Prostate cancer, Prostate specific membrane antigen",

author = "Isabel Rauscher and Tobias Maurer and Fendler, {Wolfgang P.} and Sommer, {Wieland H.} and Markus Schwaiger and Matthias Eiber",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = jun,

day = "8",

doi = "10.1186/s40644-016-0072-6",

language = "English",

volume = "16",

journal = "Cancer Imaging",

issn = "1470-7330",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - 68Ga-PSMA ligand PET/CT in patients with prostate cancer

T2 - How we review and report

AU - Rauscher, Isabel

AU - Maurer, Tobias

AU - Fendler, Wolfgang P.

AU - Sommer, Wieland H.

AU - Schwaiger, Markus

AU - Eiber, Matthias

PY - 2016/6/8

Y1 - 2016/6/8

N2 - Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.

AB - Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with 68Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and clinical guidelines for this new technique are still missing. Therefore, we summarized our experience with 68Ga-PSMA ligand PET/CT examinations in patients with primary PC and biochemical recurrence. It focuses on the technical and logistical aspects of 68Ga-PSMA ligand PET/CT examination as well as on the specific background for image reading discussing also potential pitfalls. Further, it includes relevant issues on free-text as well as structured reporting used in daily clinical routine.

KW - Positron emission tomography

KW - Prostate cancer

KW - Prostate specific membrane antigen

UR - http://www.scopus.com/inward/record.url?scp=84975278305&partnerID=8YFLogxK

U2 - 10.1186/s40644-016-0072-6

DO - 10.1186/s40644-016-0072-6

M3 - Review article

C2 - 27277843

AN - SCOPUS:84975278305

SN - 1470-7330

VL - 16

JO - Cancer Imaging

JF - Cancer Imaging

IS - 1

M1 - 14

ER -